Invitrogen and Applied Biosystems, who expect their $6.7 billion merger to be completed in late October or early November, this week named the following to the management team of the combined firm: David Hoffmeister, currently Invitrogen’s CFO, will assume the same position at the new company; Bernd Brust, head of invitrogen’s global sales and marketing, will head global commercial operations; Peter Leddy, head of Invitrogen’s human resources, will become head of global human resources; Mark O’Donnell, now head of ABI”s global services and supply chain, will lead global operations and services; John Cottingham, general counsel for Invitrogen, will become chief legal officer; Paul Grossman, Invitrogen’s lead for strategy and corporate development, will assume the same title; Joe Beery will take on the same title he currently holds at Invitrogen, head of information technology; Brian Pollock, CSO of Invitrogen will be head global research and development; and Mark Smedley will continue as full-time integration leader and head of the Integration Management Office. He has been directing the integration efforts.
The two companies also announced the creation of four divisions that will comprise the newly combined firm and its division heads [See briefs, this issue].
Power3 Medical Products last week appointed Helen Park its interim CEO, replacing Steven Rash, who resigned as CEO and chairman of the board earlier this month. Park’s appointment became effective on Sept. 7
Ira Goldknopf, Power3’s sole remaining director, was appointed president and interim board chairman. He remains as the company’s chief scientific officer and director of proteomics.
Park has more than 40 years in science and biotechnology business management. She and Goldknopf co-founded Advanced BioChem, where she was CEO and chairwoman. She was also founder and CEO of contracting and consulting firm Bronco Technology.